T
Tremelimumab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Patient Medication Guide
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Medical Assistance Fund
Active ingredient: Tremelimumab
General information
Subsidy Information and Financing Scheme
[MAF] Tremelimumab (Imjudo) Concentrate For Solution For Infusion 300 mg/15 mL
A single priming dose of tremelimumab in combination with durvalumab for treating unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.
[MSHL] Tremelimumab Concentrate For Solution For Infusion 300 mg/15 mL
Durvalumab in combination with a single priming dose of tremelimumab for treating unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion, and tremelimumab 300 mg/15 mL concentrate for solution for infusion, to be used according to the STRIDE regimen (single-dose tremelimumab in combination with regular-interval durvalumab) for treating unresectable hepatocellular carcinoma. Patients must not have received prior systemic therapy and must have adequate liver function as assessed by the Child-Pugh scoring system.
Funding status
[R] Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion, and tremelimumab 300 mg/15 mL concentrate for solution for infusion, are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.
Clinical indication, subsidy class and MediShield Life claim limits for durvalumab and tremelimumab are provided in the Annex.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Imjudo Concentrate For Solution For Infusion 300 mg/15 mL |
|